PMID- 22825654
OWN - NLM
STAT- MEDLINE
DCOM- 20130219
LR  - 20211021
IS  - 1436-2813 (Electronic)
IS  - 0941-1291 (Linking)
VI  - 42
IP  - 10
DP  - 2012 Oct
TI  - Effects of a proton pump inhibitor on the physiological accumulation of 
      fluoro-2-deoxy-D-glucose (FDG) in FDG-positron emission tomography.
PG  - 927-33
LID - 10.1007/s00595-012-0265-y [doi]
AB  - PURPOSES: The physiological accumulation of fluoro-2-deoxy-D-glucose (FDG) is 
      common in medical examinations of the digestive tract conducted using 
      FDG-positron emission tomography (PET). The aim of this study was to determine 
      the effects of a proton pump inhibitor (PPI) on the physiological FDG 
      accumulation in the digestive tract. METHODS: A total of 130 patients examined 
      from July 2007 to October 2008 were included in the final analysis. A PPI was 
      administered orally prior to FDG-PET in 65 patients. The remaining 65 patients 
      underwent FDG-PET without administration of the PPI. The assessments used visual 
      and quantitative evaluations. RESULTS: Visual evaluation showed that 
      physiological FDG accumulation in the stomach was significantly reduced (p = 
      0.037) in the PPI group compared with the control group. The quantitative 
      evaluation also revealed a significant reduction in the maximum standardized 
      uptake values (SUV(max)) in the stomach in the PPI group compared with the 
      control group (p < 0.0001). Physiological FDG accumulation in the colon showed a 
      decreasing trend on visual evaluation in the PPI group compared with the control 
      group, and the quantitative evaluation found a significant reduction in the 
      physiological FDG accumulation in the colon in the PPI group (p = 0.045). 
      CONCLUSIONS: The oral administration of a PPI was effective for reducing the 
      physiological accumulation of the FDG in the alimentary tract. However, based on 
      the error associated with SUV(max) measurement, a quantitative evaluation should 
      therefore be combined with the visual evaluation.
FAU - Domeki, Yasushi
AU  - Domeki Y
AD  - Department of Surgical Oncology (Surgery I), Dokkyo Medical University, 880 
      Kitakobayashi, Mibu-machi, Tochigi 321-0293, Japan. y-domeki@dokkyomed.ac.jp
FAU - Yamazaki, Erena
AU  - Yamazaki E
FAU - Matsuura, Akira
AU  - Matsuura A
FAU - Kitajima, Kazuhiro
AU  - Kitajima K
FAU - Murakami, Koji
AU  - Murakami K
FAU - Kato, Hiroyuki
AU  - Kato H
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20120724
PL  - Japan
TA  - Surg Today
JT  - Surgery today
JID - 9204360
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
RN  - 32828355LL (Rabeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage/*pharmacology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Colon/drug effects/*metabolism
MH  - Drug Administration Schedule
MH  - Female
MH  - Fluorodeoxyglucose F18/*pharmacokinetics
MH  - Gastric Mucosa/*metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Multimodal Imaging
MH  - Neoplasms/diagnostic imaging
MH  - *Positron-Emission Tomography
MH  - Proton Pump Inhibitors/administration & dosage/*pharmacology
MH  - Rabeprazole
MH  - Radiopharmaceuticals/*pharmacokinetics
MH  - Stomach/drug effects
MH  - Tissue Distribution/drug effects
MH  - *Tomography, X-Ray Computed
EDAT- 2012/07/25 06:00
MHDA- 2013/02/21 06:00
CRDT- 2012/07/25 06:00
PHST- 2011/04/13 00:00 [received]
PHST- 2011/06/27 00:00 [accepted]
PHST- 2012/07/25 06:00 [entrez]
PHST- 2012/07/25 06:00 [pubmed]
PHST- 2013/02/21 06:00 [medline]
AID - 10.1007/s00595-012-0265-y [doi]
PST - ppublish
SO  - Surg Today. 2012 Oct;42(10):927-33. doi: 10.1007/s00595-012-0265-y. Epub 2012 Jul 
      24.